1608 results about "Coccus" patented technology

The invention relates to recombinant escherichia coli THRS-6 and a method for synthesizing L-threonine by using the recombinant escherichia coli THRS-6. The invention belongs to the technical field of bioengineering, and relates to an aspartic acid kinase thrAmut and pyridine nucleotide transhydrogenase pntAB gene derived from escherichia coli, an aspartic acid dehydrogenase aspDH gene derived from pseudomonas aeruginosa, a hemoglobin vgb gene derived from vitreoscilla and a transcriptional regulation factor irrE gene derived from radiococcus. The recombinant escherichia coli is used as a substrate, the ldhA gene is knocked out to further modify the recombinant escherichia coli, the recombinant escherichia coli THRS-6 with glucose as the substrate is obtained, the THRS-6 is used for fermentation, and the yield and conversion rate of the L-threonine are obviously improved.

The invention relates to the technical field of animal feed preparation, in particular to a functional feed additive for ruminants and a preparation method of the functional feed additive for the ruminants, and the functional feed additive for the ruminants is characterized by consisting of the following components in percentage by mass: probiotics which are saccharomycetes, bacillus subtilis and enterococcus faecalis; an enzyme preparation, xylanase and protease; prebiotics are added; a microcapsule coating material; a binder; the balance is a carrier; the probiotics and the enzyme preparation are wrapped in the chitosan / sodium alginate composite film through a microcapsule coating technology, adverse factors such as temperature, humidity and illumination in the production, transportation and storage process can be effectively isolated, meanwhile, in the rumen low-pH, strong-protease and complex-microorganism environment, the coating layer can slowly release and protect active ingredients, and the effect of preventing and treating the probiotics and the enzyme preparation is achieved. Effective content and activity during final feeding are ensured, consistent growth promotion can be kept in different varieties, weights and feeding stages, and production benefits and feeding stability are improved.

The invention relates to the technical field of food processing, in particular to oat fermented milk and a preparation method thereof, and the preparation method comprises the following steps: respectively preparing bacterial suspensions of TZ3-1-2, TG8-1-9 and QF-1-1; adding the TZ3-1-2 bacterial suspension and the TG8-1-9 bacterial suspension into the oat juice, and carrying out lactic acid bacteria fermentation to obtain a lactic acid bacteria fermentation product; adding the QF-1-1 bacterial suspension into the lactic acid bacteria fermentation product for yeast fermentation to obtain a yeast fermentation product; and carrying out after-ripening catalysis on the yeast fermentation product to obtain the oat fermented milk. The lactic acid bacteria TZ3-1-2 are pediococcus pentosaceus, and the preservation number of the lactic acid bacteria TZ3-1-2 is CGMCC (China General Microbiological Culture Collection Center) No.32259; the lactic acid bacteria TG8-1-9 are lactobacillus plantarum, and the preservation number of the lactic acid bacteria TG8-1-9 is CGMCC (China General Microbiological Culture Collection Center) No.32258. The lactic acid bacteria TG8-1-9 are lactobacillus plantarum. According to the method, mixed fermentation and two-stage sequential fermentation technologies are utilized, the fermentation time is shortened, meanwhile, the defects of single fermentation are effectively overcome, and finally the oat fermented milk which is excellent in taste and good in tissue state in all aspects is obtained.

The invention provides an antibacterial peptide cAMP048 sourced from microorganisms in a deep sea environment and application of the antibacterial peptide cAMP048, and belongs to the technical field of peptide inhibitors. The antibacterial peptide cAMP048 has an amino acid sequence as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The antibacterial peptide can inhibit the growth of acinetobacter baumannii at 64 mu M, inhibit the growth of multi-drug-resistant acinetobacter baumannii and multi-drug-resistant enterococcus faecium at 128 mu M and inhibit the growth of escherichia coli, staphylococcus aureus and multi-drug-resistant klebsiella pneumoniae at 256 mu M. The antibacterial peptide can be used for preparing products with antibacterial and / or bactericidal performance, and can be applied to preparation of antibacterial and / or bactericidal products. Such as food, skin care products or medical supplies.

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.

The invention relates to lactobacillus gasseri FMTA1125B with the effect of preventing, relieving or treating vaginitis and application of the lactobacillus gasseri FMTA1125B. The lactobacillus gasseri FMTA1125B is classified and named as lactobacillus gasseri, and the preservation number of the lactobacillus gasseri FMTA1125B is CGMCC No.34292. The lactobacillus gasseri FMTA1125B has the effects of preventing, relieving or treating vaginitis and the application of the lactobacillus gasseri FMTA1125B. The bacterium can produce beneficial components such as lactic acid, gamma-aminobutyric acid and hydrogen peroxide through metabolism so as to regulate the genital tract environment and improve the health degree; and the traditional Chinese medicine composition has relatively good bacteriostasis and sterilization effects on common vaginal pathogenic bacteria such as escherichia coli, staphylococcus aureus, gardnerella vaginalis, candida albicans, neisseria gonorrhoeae and the like. Therefore, the lactobacillus gasseri FMTA1125B strain can be used for preparing a preparation with the effect of improving related genital tract diseases such as vaginitis.

The invention discloses an antibacterial peptide SAMP4 or a derivative thereof, a pharmaceutical composition and application, and belongs to the technical field of biology, the amino acid sequence of the antibacterial peptide SAMP4 is as shown in SEQ ID NO: 1, and the antibacterial peptide SAMP4 has a broad-spectrum antibacterial effect and can be used for preparing antibacterial peptide SAMP4. The compound has a strong bacteriostatic effect on various gram-positive bacteria such as staphylococcus aureus, enterococcus and streptococcus and various gram-negative bacteria such as escherichia coli, acinetobacter baumannii and pseudomonas aeruginosa, and is strong in antibacterial activity, wide in antibacterial spectrum and low in toxicity. The invention also provides a derivative and a salt of the antibacterial peptide SAMP4 and application of the antibacterial peptide SAMP4 and the derivative and the salt of the antibacterial peptide SAMP4 to research, development and preparation of various antibacterial products or / and antibacterial drugs and treatment of bacterial infectious diseases, and the antibacterial peptide SAMP4 and the derivative and the salt of the antibacterial peptide SAMP4 are remarkable in advantages and wide in application prospect.

The invention discloses lactococcus gasseri C6a2 and application thereof. The preservation number of the lactococcus gasseri C6a2 is CGMCC (China General Microbiological Culture Collection Center) NO: 31024; the 16S rRNA (ribosomal Ribonucleic Acid) gene sequence of the lactococcus gasseri C6a2 is as shown in SEQ ID NO: 1. The bacterial strain is a macrobrachium rosenbergii intestinal absolute dominant bacterium, has a typical probiotic function, is high in growth speed and activity, can quickly enter a logarithmic phase, has relatively high acid production and acid resistance, can secrete lipase, has relatively high bacteriostatic activity on staphylococcus aureus, aeromonas hydrophila and aeromonas veronii, and can be used for preparing the macrobrachium rosenbergii. The bacterium can be used for preparing a special probiotic preparation for macrobrachium rosenbergii, so that the sustainable development of the macrobrachium rosenbergii industry in China is promoted.

The invention relates to the technical field of biomineralization, and particularly discloses an alkali-resistant urease-producing microbial flora for biomineralization of construction joints and a preparation method of the alkali-resistant urease-producing microbial flora. The microbial flora disclosed by the invention is prepared from the following strains with relative abundance: 4.4 to 5.2 percent of bacillus, 0.39 to 0.46 percent of enterococcus, 4.8 to 5.7 percent of alcaligenes, 0.50 to 0.58 percent of cellulomonas, 22.4 to 24.2 percent of lysobacter, 1.7 to 2.4 percent of pseudomonas, 10.8 to 11.9 percent of Savagea, 15.1 to 16.2 percent of sarcina, 30.8 to 32.2 percent of chloridomonas and 0.41 to 0.48 percent of bacillus. The alkali-resistant microbial compound flora with high urease activity in the limited oxygen and normal environment can effectively overcome the defects that urease microorganisms are low in mineralization efficiency under the anoxic condition, and the strength of an obtained consolidated body is not high.

The invention relates to pediococcus pentosaceus with a cholesterol lowering function and application thereof, and belongs to the technical field of microorganisms. The invention discloses pediococcus pentosaceus with a cholesterol lowering function and application of the pediococcus pentosaceus. The pediococcus pentosaceus R5 (GDMCC No.65659) is separated from special fermented food stinky acid in Guizhou. The in-vitro cholesterol removal rate of the pediococcus pentosaceus R5 can reach 59%, and the pediococcus pentosaceus R5 has the characteristics of acid / cholate resistance, no hemolysis and sensitivity to common antibiotics; an in-vivo lipid-lowering experiment is carried out on a hyperlipidemia model mouse, and the result shows that the strain R5 can remarkably improve the in-vivo dyslipidemia state of the mouse, reduce liver fat accumulation and protect the liver at the same time, and can be used for developing lipid-lowering related probiotic functional products. The strain R5 provided by the invention provides a natural and safe probiotic for preventing and / or treating hyperlipemia.

The invention discloses an intestinal flora marker related to Parkinson's syndrome and application of the intestinal flora marker. The invention discloses an intestinal flora marker, which comprises one or a combination of more of bacteroides faecalis, bacteroides vulgaris, bacteroides thetaotamicrobe, ruminococcus ruminococcus and lactobacillus salivarius, and is characterized in that the intestinal flora marker comprises one or a combination of more of bacteroides faecalis, bacteroides vulgaris, bacteroides thetaotamicrobe, ruminococcus ruminococcus and lactobacillus salivarius, and the intestinal flora marker comprises one or a combination of more of the bacteroides vulgaris, the bacteroides vulgaris, the bacteroides thetaotamicrobe, the ruminococcus ruminococcus and the lactobacillus salivarius. The intestinal flora marker is used as a detection marker to be applied to diagnosis of Parkinson's syndrome patients, and is completely noninvasive and high in accuracy.

The invention relates to a bifidobacterium animalis subsp. Lactis YYSJ001 with a blood sugar reducing effect and application of the bifidobacterium animalis subsp. Lactis YYSJ001. The classification name of the strain is bifidobacterium animalis subsp. Lactis, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.33471. The invention further relates to a preparation method of the bifidobacterium animalis subsp. Lactis YYSJ001. The bacterial strain has good artificial gastric juice resistance, artificial intestinal juice resistance and intestinal tract adhesion ability, has an inhibition effect on numerous pathogenic bacteria such as escherichia coli, staphylococcus aureus, salmonella, klebsiella pneumoniae and quail chicken enterococcus, and can stimulate intestinal cells to generate glucagon-like peptide-1, so that the bacterial strain can be applied to preparation of various pathogenic bacteria. Diseases of diabetic mice can be effectively improved, and the compound can be used for preparing products for preventing and treating diabetes or assisting in reducing blood sugar.

The invention discloses pediococcus acidilactici and application thereof, and relates to the technical field of microorganisms. The pediococcus acidilactici is pediococcus acidilactici Mei.1103.1, the preservation unit is China General Microbiological Culture Collection Center, the preservation number is CGMCC NO.32564, the preservation date is November 11, 2024, the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1 is CGMCC NO.32564. The pediococcus acidilactici Mei.1103.1. The invention also provides application of the fermented dry rice flour in preparation of products for reducing uric acid, preventing / treating hyperuricemia, regulating immunity, preventing / treating kidney injury and preventing / treating fatty liver and fermented dry rice flour. The bacterium can reduce uric acid and relieve hyperuricemia; regulating blood fat; kidney and liver injuries caused by hyperuricemia are repaired; the content of volatile flavor compounds in the fermented dry rice flour is increased.

The invention belongs to the field of microorganisms. The invention provides a compound strain, a microbial inoculum and application of the compound strain in preparation of fermented East purple perilla tea. The compound strain comprises phytobacterium plantarum 2HDS3-La5 with the preservation number of CGMCC NO.34339, pediococcus acidilactici 2HDS3-SM6 with the preservation number of CGMCC NO.34337, Witzmania clostridium N2-La1 with the preservation number of CGMCC NO.34338, and the microbial inoculum is applied to preparation of fermented East purple perilla tea. The invention also provides application of the compound strain or a microbial inoculum containing the compound strain in preparation of fermented East purple perilla tea. The compound strain disclosed by the invention is applied to preparation of the fermented Dongbao tea, the content of substances with anti-inflammatory, anti-oxidation and immunoregulation effects in the Dongbao tea is remarkably increased by multiple times, and the prepared fermented Dongbao tea can remarkably improve the cell activity.

The invention discloses pediococcus pentosaceus CCFM1402 capable of effectively repairing a skin barrier and a self-fermentation metabolite of the pediococcus pentosaceus CCFM1402, and belongs to the technical field of microorganisms and medicines. The pediococcus pentosaceus CCFM1402 provided by the invention has the effect of improving the skin barrier function in both external use and oral administration; the cell activity of damaged HaCaT cells and the expression of the gene level of skin barrier function protein and tight junction protein can be improved by virtue of a thallus lysate and a fermented supernatant (metagen) of the external pediococcus pentosaceus CCFM1402; and the DNFB-induced mouse skin barrier injury can be relieved in the aspects of appearance, skin barrier protein expression and the like by orally taking viable bacteria and postbiotics of the pediococcus pentosaceus CCFM1402. Therefore, the pediococcus pentosaceus CCFM1402 has a huge application prospect in preparation of external or oral medicines for repairing the skin barrier and preparation of food, health care products or cosmetics.

The invention belongs to the technical field of microorganisms, and particularly relates to probiotic characteristics of lactic acid bacteria and a relieving effect of a metagen of the lactic acid bacteria on pulmonary fibrosis. The invention discloses pediococcus pentosaceus ZFML001, and the preservation number of the pediococcus pentosaceus ZFML001 is CCTCC (China Center for Type Culture Collection) NO: M 2024601. The invention also provides a metagen prepared from the pediococcus pentosaceus ZFML001 at the same time, and provides an application of the metagen in preparation of a medicine for relieving or assisting in treatment of pulmonary fibrosis. The invention further provides the application of the metagen in preparation of a medicine for relieving or assisting in treatment of pulmonary fibrosis.

The present disclosure provides a vaccine composition wherein the antigen components comprise a factor H binding protein (fHbp), a recombinant outer membrane vesicle (OMV) carrying porin A (PorA protein), and optionally a heparin binding protein (NHBA protein). The antigen components in the vaccine composition disclosed by the invention have a good synergistic effect, so that the vaccine composition has extremely high vaccine forming potential, is used for preventing epidemic of group B meningococcus, and plays a role in protecting infection of group B meningococcus.

The invention discloses a composition for treating insomnia. Comprising probiotic compounds: lactobacillus plantarum, bifidobacterium lactis, lactobacillus crispatus, lactobacillus acidophilus, lactobacillus rhamnosus, bifidobacterium bifidum, lactobacillus reuteri, lactobacillus casei, lactobacillus bulgaricus, lactobacillus fermentum, lactobacillus gasseri, lactococcus lactis, bifidobacterium longum, lactobacillus salivarius, bifidobacterium breve, streptococcus thermophilus and lactobacillus paracasei; lactobacillus helveticus; and traditional Chinese medicine components and prebiotics. Probiotics are matched with traditional Chinese medicines with homology of medicine and food, and corresponding prebiotics are supplemented, so that the balance of intestinal flora can be adjusted and information transmission between intestines and cranial nerves can be promoted through the synergistic effect of the probiotics and the corresponding prebiotics, and then gastrointestinal inflammation, ulcer, helicobacter pylori infection, constipation and insomnia are treated or improved; and treating or improving spleen and stomach disharmony, liver qi stagnation, excessive heart fire, fire excess from yin deficiency, heart-kidney disharmony caused by emotion, pressure, diseases and the like, and insomnia caused by the symptoms.

The invention discloses pediococcus acidilactici NDF12 and application thereof, the pediococcus acidilactici NDF12 is preserved in Guangdong Microbial Culture Collection Center on January 8, 2025, is called GDMCC for short, and the preservation number is GDMCC NO: 65732. The invention further discloses a preparation method of the pediococcus acidilactici NDF12. The strain is derived from Chinese local traditional dairy products, phenotype and genotype safety evaluation proves that the strain is safe and non-toxic, has excellent fermentation characteristics and probiotic characteristics, and can be used as a leavening agent for producing yoghourt. The bacterial strain also has gastrointestinal fluid endurance capacity, adhesion capacity, bacteriostatic activity, antioxidant activity, cholesterol lowering activity and blood sugar lowering activity, and has great application prospects in the fields of foods, medicines, feeds and the like.

The invention relates to the technical field of new strains, and provides a new strain which is screened from Xinjiang saline-alkali soil, is classified and named as sphingomonas sp. And is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCCNO.32220. Research finds that the strain can remarkably reduce the soil conductivity, the exchangeable sodium content, the alkalization degree and the total salt content, so that the soil quality is improved. The organic matter content and the acid phosphatase activity of the soil are remarkably improved, and the quality of the saline-alkali soil can be efficiently improved. Meanwhile, the invention provides a compound bacterial fertilizer for effectively improving saline-alkali soil, the compound bacterial fertilizer comprises bacillus subtilis, Exiguobacterium acetylbacter, Bacillus velezensis, Pseudomonas fluorescens, Rhodococcus capsulatus and a new strain Sphingomonas sp., and research finds that compared with a single bacterial solution, the compound bacterial solution has a more prominent remediation effect on saline-alkali soil.

The invention is applicable to the technical field of polypeptides, and provides a novel antibacterial peptide GG25 and application thereof, and the amino acid sequence of the antibacterial peptide GG25 is as shown in SEQ ID No.1. The molecular weight of the novel antibacterial peptide GG25 is 2890.52 Da, and the novel antibacterial peptide GG25 has antibacterial activity on escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, enterococcus faecalis, salmonella typhimurium, methicillin-resistant staphylococcus aureus, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and bacillus subtilis; the hemolytic activity is low, the cytotoxicity is small, and the escherichia coli and methicillin-resistant staphylococcus aureus are not easily induced to generate drug resistance; in addition, the gelatin chitosan food coating containing GG25 also has a good beef preservation effect, and can be applied to the fields of food, animal husbandry, medicine and the like.

The invention relates to the technical field of fermentation, in particular to a strain of lactococcus gasseri ZB15, an acellular fermentation freeze-dried substance with anti-inflammatory activity and a preparation method of the acellular fermentation freeze-dried substance. The Lactococcus garvieae ZB15 is preserved in the Guangdong Microbial Culture Collection Center, the address is the 5th floor of building 59, No.100 Courtyard, Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences, the preservation date is February 27, 2025, and the preservation number is GDMCC No: 65947. The lactococcus gasseri ZB15 disclosed by the invention is prepared into an acellular fermentation freeze-dried substance, and the acellular fermentation freeze-dried substance can improve the body immunity by changing the intestinal microflora structure while relieving and improving enteritis, so that a basis is provided for the preparation of enteritis medicines.

The invention belongs to the technical field of biology, and provides enterococcus faecalis, the preservation number of which is CGMCC (China General Microbiological Culture Collection Center) No.29087. The enterococcus faecalis is characterized in that the enterococcus faecalis can secrete bacteriocin for inhibiting vibrio parahaemolyticus, staphylococcus aureus and escherichia coli. The invention also provides the enterococcus faecalis and application thereof in an aquatic product fermented feed and a laying hen premix, and the enterococcus faecalis can effectively improve the utilization rate of the feed and the growth and production performance of animals.

The invention relates to the technical field of microbial deodorants, and discloses a microbial compound bacterium deodorant and a preparation method thereof.The microbial compound bacterium deodorant comprises a bacterium powder mixture, the bacterium powder mixture is embedded into a loading material, and the loading material is wrapped with a protective agent; the bacterial powder mixture comprises pediococcus acidilactici, bacillus megaterium, alcaligenes faecalis, bacillus subtilis and azotobacter chroococcum, wherein the mass ratio of the pediococcus acidilactici to the bacillus megaterium to the alcaligenes faecalis to the bacillus subtilis to the azotobacter chroococcum is 1: (1-3): (1-2): (0.5-1): (1-2). According to the microbial compound bacterium deodorant and the preparation method thereof, the prepared microbial compound bacterium deodorant can remarkably remove malodorous gases such as NH3 and H2S in biological excrement, the action time is long, the effect is remarkable, meanwhile, the raw materials of the microbial compound bacterium deodorant are green and safe, and the health problem caused by mistaken eating of livestock is solved.

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention discloses pediococcus acidilactici JW-015 as well as a selenium-rich microbial inoculum and application thereof, and belongs to the technical field of biology. According to the invention, a strain of pediococcus JW-015 which not only can be enriched with inorganic selenium, but also has oxidation resistance and ethanol tolerance is screened out, and the pediococcus JW-015 has huge potential and application value in the aspect of developing hangover-alleviating related probiotic health-care foods and medicines.

The invention relates to application of ten antibacterial peptides in the antimicrobial field. The ten antibacterial peptides have strong antibacterial activity on multi-drug-resistant bacteria, including but not limited to gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, acinetobacter baumannii, klebsiella pneumoniae and the like, and gram-positive bacteria such as staphylococcus aureus, enterococcus faecalis and the like. Activity research proves that any one of the ten antibacterial peptides has a remarkable effect of inhibiting, killing or preventing microbial infection. Due to the strong antibacterial property of any antibacterial peptide, the antibacterial peptide has wide application potential in the aspects of preparing antibacterial drugs, preservatives, antibacterial coatings, antibacterial fibers, antibacterial packaging materials and the like. Due to the unique property of the antibacterial peptide in the aspect of antibacterial performance, a new direction is provided for the development of efficient and reliable antibacterial agents and antibacterial technologies and products in multiple fields.

The invention belongs to the technical field of antibacterial active microorganisms, and particularly relates to a strain of diffusion carbon pad bacteria LUCF 4343-3, a bacterial agent and application of the bacterial agent in preparation of an antibacterial preparation. According to the invention, an endophytic fungus strain with remarkable antibacterial potential is successfully separated from Parmotrema, and the endophytic fungus strain is identified as diffusion carbon pad fungus LUCF 4343-3. Experiments show that an ethyl acetate extract of the strain shows a good inhibition effect on various clinical common pathogenic bacteria, including gram-positive bacteria (staphylococcus aureus and enterococcus faecalis), gram-negative bacteria (pseudomonas aeruginosa), fungi (candida albicans and candida glabrata) and the like; the discovery provides an important basis for the application of the strain in the development of novel broad-spectrum antibacterial drugs.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention discloses a functional probiotic composition and application thereof, and relates to the technical field of microbial engineering. Bifidobacterium longum, lactobacillus acidophilus and enterococcus faecalis are combined to serve as a microbial agent, the microbial agent and active substances of the tea leaves form a composition, then the composition is combined with prebiotics, it is ensured that viable bacteria directly reach the intestinal tract through a microencapsulation technology, and the effect of improving the immune function is achieved; tea polyphenol in the active substances of the tea leaves can serve as a carbon source of prebiotics to stimulate proliferation of the bifidobacterium longum and the lactobacillus acidophilus, so that the acid resistance and intestinal colonization capacity of the microbial inoculum are enhanced, and meanwhile, theanine in the active substances of the tea leaves, the bifidobacterium longum and the lactobacillus acidophilus synergistically promote secretion of gamma-aminobutyric acid, so that the effect of improving the intestinal colonization is achieved. And the tea polyphenol can inhibit the large intestine rod from adhering to the intestinal mucosa, and the probiotic agent secretes antibacterial peptide, so that the integrity of the intestinal barrier is maintained together.